ICU机械通气期间早期主动活动的成本效果:TEAM试验的经济学评价
该研究为TEAM随机对照试验的前瞻性组内成本效果分析,纳入6个国家49个ICU的733例接受有创机械通气的成人患者,比较早期主动活动与常规活动。结果显示两组增量成本无显著差异(1823美元;95%CI,-10552至12027美元),6个月EuroQoL-5D五水平效用评分无显著差异(0.532 vs 0.548;P=0.585)。早期主动活动具有成本效果的概率低于50%,即使支付意愿阈值为20万美元/QALY。敏感性分析纳入Meta分析数据提示早期主动活动可能节省成本,但伴随更低的QALY增益。
要点
- 在733例有创机械通气成人ICU患者中,早期主动活动与常规活动相比增量成本无显著差异(1823美元;95%CI,-10552至12027美元)。
- 6个月EuroQoL-5D五水平效用评分两组无显著差异(早期主动活动0.532 vs 常规活动0.548;P=0.585)。
- 早期主动活动具有成本效果的概率低于50%,即使支付意愿阈值高达20万美元/QALY。
- 敏感性分析纳入Meta分析数据提示早期主动活动可能节省成本,但伴随更低的QALY增益。
- 作者结论认为无证据表明高剂量早期主动活动相对于常规活动具有成本效果,需进一步研究确定是否存在能提供经济价值的场景。
适用人群与场景
- 纳入TEAM研究的733例成人ICU患者,均接受有创机械通气。
- 研究在6个国家(澳大利亚、新西兰、英国、爱尔兰、德国和巴西)的49个ICU进行。
处置流程与药物剂量
- 干预为早期主动活动,对照为常规活动;原文未给出具体活动方案、剂量、频次或目标值。
研究设计与关键结果
- 研究设计:前瞻性、组内成本效果分析,依托TEAM随机对照试验。
- 样本量:733例成人ICU患者,来自6个国家49个ICU。
- 干预与对照:早期主动活动 vs 常规活动。
- 主要结果:增量成本无显著差异(1823美元;95%CI,-10552至12027美元)。
- 6个月EuroQoL-5D五水平效用评分无显著差异(早期主动活动0.532[se,0.021] vs 常规活动0.548[se,0.021];P=0.585)。
- 早期主动活动具有成本效果的概率低于50%,即使支付意愿阈值为20万美元/QALY。
- 敏感性分析纳入Meta分析数据提示早期主动活动可能节省成本,但伴随更低的QALY增益。
证据类型、等级与局限
- 证据类型:基于随机对照试验的前瞻性成本效果分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于接受机械通气的成人ICU患者,无证据表明高剂量早期主动活动相对于常规活动具有成本效果。
- 作者认为,敏感性分析提供了一些证据表明早期主动活动可能节省成本,但前提是愿意接受更差的结局。
- 作者建议需进一步研究以确定是否存在早期主动活动能提供经济价值的场景。
指南或共识出处
- 重症医学会ICU解放集束化推荐早期活动。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Early mobilization is recommended by the Society of Critical Care Medicine ICU Liberation Bundle. The Treatment of Mechanically Ventilated Adults With Early Activity and Mobilization (TEAM) randomized controlled trial (RCT) compared early active mobilization to usual care mobilization and found no difference in the primary outcome of days alive and out of hospital to day 180; however, it did find an increase in adverse events in the intervention group. To date, no RCT of early mobilization has reported costs or cost-effectiveness. We aimed to determine the cost-effectiveness of early active mobilization from the perspective of the healthcare sector.
DESIGN: We conducted a prospective, within-trial cost-effectiveness analysis alongside the TEAM study.
SETTING: Forty-nine ICUs in six countries (Australia, New Zealand, United Kingdom, Ireland, Germany, and Brazil).
PATIENTS: The cost-effectiveness analysis included 733 adult ICU patients who were undergoing invasive mechanical ventilation and enrolled in the TEAM study.
INTERVENTIONS: Early active mobilization or usual care mobilization.
MEASUREMENTS AND MAIN RESULTS: A significantly higher number of hours were spent by staff in delivering high-dose early active mobilization vs. usual care mobilization; however, incremental costs were not significantly different between the groups ($1,823; 95% CI, -$10,552 to $12,027). EuroQoL-5D 5-level utility scores at 6 months were not significantly different between the groups (0.532 [ se , 0.021] vs. 0.548 [ se , 0.021]; p = 0.585). The probability of early active mobilization being cost-effective is less than 50%, even at a willingness-to-pay threshold of $200,000/quality-adjusted life year (QALY). Sensitivity analyses incorporating meta-analysis data indicated that early active mobilization may be cost-saving; however, this involves the occurrence of lower QALY gains when compared with usual care mobilization.
CONCLUSIONS: Our trial-based analysis found no evidence that higher-dose early active mobilization is a cost-effective intervention compared with usual care mobilization for mechanically ventilated adult ICU patients; however, results from sensitivity analyses provided some evidence that it may be cost saving if one is willing to accept poorer outcomes. Further research is necessary to determine whether there are scenarios in which early active mobilization provides value for money.
参考来源
- Higgins AM, Lee YY, Bailey M, et al. The Cost-Effectiveness of Early Active Mobilization During Mechanical Ventilation in the ICU: An Economic Evaluation Alongside the Treatment of Mechanically Ventilated Adults With Early Activity and Mobilization (TEAM) Trial. Crit Care Med. 2025. PMID: 40439527. doi:10.1097/CCM.0000000000006715
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。